Nation’s largest Pharmacy Benefits Manager accused of gaming its drug formulary and withholding billions in rebates from PBM customers. NEW YORK–(BUSINESS WIRE)–Nation’s largest Pharmacy Benefits Manager accused of gaming its drug formulary and withholding billions in rebates from PBM customers. NEW YORK–(BUSINESS WIRE)–

Bernstein Litowitz Berger & Grossmann Announces Filing of Racketeering Class Action Against Express Scripts

2026/02/18 06:30
4 min read

Nation’s largest Pharmacy Benefits Manager accused of gaming its drug formulary and withholding billions in rebates from PBM customers.

NEW YORK–(BUSINESS WIRE)–Today, Bernstein Litowitz Berger & Grossmann LLP (BLB&G) announces the filing of a class action against Express Scripts – the nation’s largest Pharmacy Benefits Manager (PBM) – and its parent companies, Cigna and Evernorth. BLB&G filed this action on behalf of the Plumbers’ Welfare Fund, which provides healthcare benefits for members of Chicago-based Plumbers Local 130. Local 130 has long been a leader in advocating for labor rights and expanding healthcare access for union members and their families.

The class action, brought on behalf of Express Scripts’ PBM customers, arises from a wide-ranging fraudulent conspiracy through which defendants diverted billions of dollars in drug rebates from their PBM customers to an offshore entity to enrich themselves. Through this scheme, Express Scripts breached its duty to develop and manage a drug formulary – the list of drugs readily available to its PBM customers – to maximize cost efficiency and efficacy for its customers.

Here is a link to the court filing: https://static.blbglaw.com/docs/ESI%20Complaint_file-stamped%202.17.26.pdf.

Nationally recognized labor leader James F. Coyne, the Business Manager of Plumbers Local 130 and Co-Chairman of the Plumbers’ Welfare Fund, stated that “For far too long, America’s working men and women who rely on our corporate healthcare system have been grossly overcharged, and denied access to affordable care. A major corporation like Express Scripts, that takes kickbacks from drug companies rather than protecting the interests of its clients, needs to be held accountable.”

This fraudulent scheme directly contravened Defendants’ numerous promises to lower healthcare costs. Express Scripts told its clients that it “exists to lower the cost of medications” and that “Express Scripts negotiates with drug companies to lower the cost of medications included on our clients’ formularies.” Express Scripts further represented to its customers that it would select drugs for the formulary based on cost and effectiveness.

Express Scripts breached these promises by demanding kickbacks from drug manufacturers in exchange for beneficial placement of certain drugs on its formulary, and excluding lower cost competitor drugs. In essence, Express Scripts sold drug manufacturers access to its formularies, which dictate the drugs available to Express Scripts’ PBM customers. Rather than extracting kickbacks in exchange for formulary access, Express Scripts should have negotiated with drug companies to maximize rebates for its PBM clients. Defendants’ misconduct caused significant harm to the Plumbers’ Welfare Fund and the thousands of other PBM clients that counted on Express Scripts to lower their prescription drug costs.

Because Express Scripts’ contract with PBM clients says that some or all money that Express Scripts receives from drug companies must be paid to customers as rebates, Express Scripts did not want to receive kickbacks directly from the drug companies. In order to hide those kickbacks, Express Scripts created Ascent, an offshore vehicle in Switzerland to receive those monies from drug companies.

Through Ascent, Express Scripts obtained billions of dollars in kickbacks, falsely characterizing them as “fees.” According to a former Express Scripts and Cigna executive cited in the complaint, “there are lots of different fees you can charge” through Ascent: “You can charge data fees. You can charge administrative. You can charge clinical fees” which enabled Defendants to “double, triple dip on fees.” Extracting kickbacks from drug companies rather than maximizing rebates directly contradicted Defendants’ promise that “Rebates are not secret or hidden payments.”

By funneling kickbacks to Ascent, Defendants side-stepped provisions in PBM customer contracts requiring that money Express Scripts received from drug companies constituted rebates that must be shared with its customers.

Avi Josefson, a senior partner at BLB&G, said, “This is simply the latest example of healthcare companies abusing a highly complex, intentionally opaque system to take advantage of their customers. This kind of misconduct increases costs and limits access for millions of Americans and can no longer be tolerated.”

ABOUT BLB&G
Bernstein Litowitz Berger & Grossmann LLP prosecutes class and private actions on behalf of individual and institutional clients worldwide. Since its founding in 1983, the firm has recovered more than $40 billion in cases ranging from securities fraud to healthcare fraud to racial discrimination. BLB&G is widely recognized as a preeminent litigation firm with a deep commitment to holding corporations responsible for their misconduct.

Contacts

Avi Josefson avi@blbglaw.com
Peter Russell peter.russell@blbglaw.com

Market Opportunity
Gravity Logo
Gravity Price(G)
$0,003991
$0,003991$0,003991
-1,04%
USD
Gravity (G) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Today’s Biggest Crypto Movers: Winners & Losers

Today’s Biggest Crypto Movers: Winners & Losers

Today's Biggest Crypto Movers: Winners & Losers Crypto Market Update 📊 Today's top movers show mixed signals. Let's dive into which cryptos made the biggest waves
Share
Blockchainmagazine2026/02/18 13:00
Altcoins Poised to Benefit from SEC’s New ETF Listing Standards

Altcoins Poised to Benefit from SEC’s New ETF Listing Standards

The post Altcoins Poised to Benefit from SEC’s New ETF Listing Standards appeared on BitcoinEthereumNews.com. On Wednesday, the US SEC (Securities and Exchange Commission) took a landmark step in crypto regulation, approving generic listing standards for spot crypto ETFs (exchange-traded funds). This new framework eliminates the case-by-case 19b-4 approval process, streamlining the path for multiple digital asset ETFs to enter the market in the coming weeks. Grayscale’s Multi-Crypto Milestone Sponsored Grayscale secured a first-mover advantage as its Digital Large Cap Fund (GDLC) received approval under the new listing standards. Products that will be traded under the ticker GDLC include Bitcoin, Ethereum, XRP, Solana, and Cardano. “Grayscale Digital Large Cap Fund $GDLC was just approved for trading along with the Generic Listing Standards. The Grayscale team is working expeditiously to bring the FIRST multi-crypto asset ETP to market with Bitcoin, Ethereum, XRP, Solana, and Cardano,” wrote Grayscale CEO Peter Mintzberg. The approval marks the US’s first diversified, multi-crypto ETP, signaling a shift toward broader portfolio products rather than single-asset ETFs. Bloomberg’s Eric Balchunas explained that around 12–15 cryptocurrencies now qualify for spot ETF consideration. However, this is contingent on the altcoins having established futures trading on Coinbase Derivatives for at least six months. Sponsored This includes well-known altcoins like Dogecoin (DOGE), Litecoin (LTC), and Chainlink (LINK), alongside the majors already included in Grayscale’s GDLC. Altcoins in the Spotlight Amid New Era of ETF Eligibility Several assets have already met the key condition, regulated futures trading on Coinbase. For example, Solana futures launched in February 2024, making the token eligible as of August 19. “The SEC approved generic ETF listing standards. Assets with a regulated futures contract trading for 6 months qualify for a spot ETF. Solana met this criterion on Aug 19, 6 months after SOL futures launched on Coinbase Derivatives,” SolanaFloor indicated. Sponsored Crypto investors and communities also identified which tokens stand to gain. Chainlink…
Share
BitcoinEthereumNews2025/09/18 13:46
Stake vs BC.Game: Best Crypto Casino in 2026?

Stake vs BC.Game: Best Crypto Casino in 2026?

Choosing the best crypto casino isn’t simple. Compare Stake and BC.Game with our detailed breakdown to see which platform fits your style best. The post Stake vs
Share
Bitcoinchaser2026/02/18 12:40